Akebia reports Q3 2026 results as Vafseo patient count grows and VOICE, VOCAL data land

Akebia Therapeutics reported third quarter 2026 financial results and business updates on November 5, 2026. The company said approximately 11,500 patients were active on Vafseo at the end of Q3 2026, an increase of about 8.1% from the end of Q2 2026 and roughly 140% over Q3 2025.¹ The number of prescribers grew to about 1,300, up more than 7% versus the prior quarter.¹

On the clinical side, Akebia said it announced topline results in November from VOCAL, an open-label trial comparing three times weekly dosing of vadadustat to standard ESA therapy in hemodialysis patients with CKD-related anemia, which met its primary endpoint of non-inferiority to ESA based on hemoglobin change.¹ Separately, at ASN Kidney Week in October, Dr. Geoffrey A. Block of U.S. Renal Care presented late-breaking VOICE trial data showing a statistically significant safety improvement for vadadustat versus ESA on a composite measure of all-cause mortality and hospitalization, attributed mainly to fewer hospitalizations.¹

In September, Akebia said it dosed the first patient in a Phase 2 open-label basket trial of ebribafusp alfa, intended to assess safety, efficacy and pharmacokinetics in up to 30 patients with C3 glomerulopathy, lupus nephritis or IgA nephropathy, with initial data expected in 2027.¹

Looking ahead, the company said it expects Vafseo access to expand in 2027 beyond TDAPA-only patients to nearly all clinically eligible patients.¹

On finances, Akebia reported cash and cash equivalents of about $159.3 million as of September 30, 2026, up from $155.5 million at the end of June 2026.¹ The company stated it believes its existing cash, expected product, royalty, supply and license revenue, and a planned refinancing of its senior secured term loan facility will fund its operating plan for at least two years.¹